M31 Capital
M31 Labs

Capital alone does not make a paradigm shift happen.

Labs is the engine that takes the fringe technologies M31 backs and carries them across the adoption gap — from early conviction to worldwide inevitability.

Most transformative technologies die in the gap between invention and adoption.

The history of paradigm shifts is full of technologies that worked but never won — stymied by policy, starved of the right talent, mismanaged by technical founders who couldn't scale an organization, or simply unknown to the institutions that could have adopted them. The technology was right. The execution around it was not.

M31 Research identifies the shifts. Capital funds them. But between the check and the exit, a company still has to build a team, win clients, navigate regulators, secure follow-on funding, and — most critically — convince the world that a suppressed technology is actually the new default. That work is neither finance nor research. It is a distinct discipline.

Labs is M31's answer to that discipline. It exists because the firms that consistently produce paradigm-defining outcomes — Bridgewater in macro, Andreessen Horowitz in Web2, a handful of biotech incubators in their prime — all built a post-investment engine as rigorous as their pre-investment one. We're building ours from first principles, with institutional discipline applied to frontier technology.

Two objectives, pursued in parallel.

Labs is not a services bolt-on. It carries the weight of two distinct objectives, and every activity in Labs can be traced back to one of them.

Company Level

Each portfolio company is set up to succeed through to exit — with the right leaders, plan, capital, partnerships, and accountability — from the moment we invest.

Ecosystem Level

The broader technology crosses the adoption gap — policy, institutional access, public understanding, and the coalition of actors required for a fringe idea to become inevitable.

Five functions, run systematically, looped back into Research.

The Labs machine takes every new company through the same disciplined sequence. Each stage produces artifacts that compound — playbooks, case studies, and updated logic that make the next company faster and better than the last.

01

Diagnose

6 – 8 week bootcamp

Using the output of the investment evaluation, we map each company against what excellence looks like at their stage — people, plan, product, operations, security, regulatory. Gaps are surfaced, root causes diagnosed, and a development plan put in place before any other work begins.

02

Resource

Talent · Business development · Subject matter expertise

Gaps get filled from a curated network of fractional executives, operators, service providers, and industry-specific experts. Where full-time hires are needed, we run the search. Where clients and partnerships are needed, our business development function opens the doors directly.

03

Probe & Hold Accountable

Ongoing coaching and metrics cadence

Every company reports against a consistent set of milestones and metrics. CEOs are coached on a regular rhythm. When a company drifts, we intervene early and diagnose the problem together rather than watching it fail. When a company succeeds, we diagnose that too — and the lesson joins the playbook.

04

Exit & Recycle

M&A · Public markets · Token launches · Follow-on rounds

When a company is ready, Labs coaches the exit — structuring acquisitions, preparing for public markets, managing tokenization, or leading the next round. The goal is not just a return, but a return at the right moment and in the right form for both the company and the fund.

05

Systemize

Feedback loop into Research

Every diagnosis, intervention, success, and failure is documented as a case study. These feed Labs' own playbook and close the loop back to Research — updating our view of the paradigm shift, what's being adopted, and what predicts a company's survival in it.

Parallel Function

Venture Studio

When Research identifies a needed company that doesn't yet exist, Labs builds it from scratch. An interim CEO, a small technical team, and a defined MVP get us to the point where the company can be properly invested in or sold to a portfolio company that needs the capability.

Scope → MVP → Test → Scale / Sell

The work, broken open.

The Machine describes the sequence. This is what the work consists of. Labs intervenes across five recurring areas — the places where most early-stage companies stumble, and where institutional discipline applied early changes the trajectory of the company.

01
People & Culture

The single largest determinant of a startup's outcome is the quality of the founding team and the culture they build around themselves. Labs works directly on both — helping founders establish a culture where people speak openly, reflect honestly on strengths and weaknesses, and surface problems early rather than burying them.

The work is concrete: structured CEO and leadership coaching, shadow meetings to observe how teams actually operate, and disciplined use of Principles You personality assessments to give founders a shared language for talking about themselves and one another. The goal is a leadership team that knows itself well enough to evolve.

02
Organizational Design

We make sure responsibilities are clear and that the right people are matched to them. When a person is not the right click for a role, Labs helps the founder run that conversation honestly — building development plans, putting guardrails in place, or running the search for a replacement.

Most early-stage failures look like execution problems but trace back to design problems: unclear ownership, the wrong person in a critical seat, or a structure that worked at five people and no longer works at twenty. Labs catches these early and intervenes before they compound.

03
Technology

Our CTO and a near-shore software development team provide three things to every portfolio company: independent probing and auditing of the technical architecture, hands-on capacity for build work when the company is resource-constrained, and senior expertise for high-stakes architecture decisions.

Founders get a candid second opinion on technical choices that will shape their company for years — and the engineering capacity to act on what they decide.

04
Business Development

Labs opens the doors. Direct introductions to the design partners, enterprise customers, and strategic partners that early-stage companies need but don't have the relationships to reach.

This is not a passive Rolodex. We work with the founder on the right account list, make the introductions warmly, and stay engaged through the conversion — because the difference between an introduction and a closed customer is usually the work that happens in between.

05
Portfolio Synergies

The portfolio itself is one of the most underused assets in venture. Labs actively brokers joint ventures and shared go-to-market efforts between portfolio companies — pairing infrastructure providers with applications, distribution-rich companies with capability-rich ones, and connecting founders working adjacent problems.

When a paradigm shift takes hold, the companies in our portfolio should be reinforcing each other, not operating in isolation. Labs is the connective tissue that makes that happen.

These are the recurring areas. Every company also brings its own specific problems — a cap table to clean up, a regulatory body to engage, a critical hire that needs to happen in the next thirty days. Labs is built to handle those too.

Labs is not an after-market. It changes the investment decision itself.

The most consequential point about Labs is that it is embedded in how we underwrite, not bolted on afterward. Before a deal is approved, Labs sits inside the investment committee to answer a question standard due diligence does not ask:

"Can we help this company — and what will it cost?"

The answer shapes everything: the total cost of the investment, the terms we push for, the services Labs will deliver, and whether we invest at all. A brilliant company with gaps Labs cannot fill is a pass. A company with gaps Labs can close efficiently can justify a higher valuation than its standalone fundamentals would suggest — because our ownership isn't just capital, it's capacity.

Gap Assessment

Can We Fill It?

Design, brand, talent, regulatory, BD, infrastructure — Labs maps the gaps against proven in-house capabilities.

Support Intensity

Light Touch or Heavy Lift?

How much of Labs' bandwidth the company will require, priced into both the deal and the portfolio construction.

Founder Fit

Will They Use It?

Coachable founders who embrace support compound; the uncoachable destroy capital at any price. This is assessed explicitly.

The network and the machine already exist.

Labs has been built over years, not months. The core capabilities are operational today, supporting current portfolio companies while being hardened and scaled for the next fund.

80+
Advisors & Service Providers
700+
Active Relationships We Can Deploy
90+
Contracted Consultants & Coaches
4
Core Support Functions in Production

The Bridgewater Core

The heart of the network is a community of principled operators, largely Bridgewater alumni — people who understand how to diagnose root causes, build excellent organizations, and hold leaders accountable. They serve on boards, coach CEOs, and drop in fractionally when a specific problem needs a specific person.

Four Production-Ready Support Functions

Talent. Vetted fractional executives, a contracted coaching network, and full-time search capability when a company needs to hire from the ground up. Business Development. Direct introductions to enterprise clients, design partners, and strategic coalitions in the sectors we cover. Subject Matter Expertise. Domain specialists across healthcare, fintech, AI, Web3, and our emerging focus areas. Follow-on Capital. A mapped network of 20+ venture partners, 30+ family offices, and deep experience leading later-stage rounds.

A Portfolio Support Function, Not a Consulting Firm

Labs' posture with portfolio companies is explicit: we are partners in their success, not vendors selling services. Some support is delivered at no cost as a condition of the investment. Some is delivered at-cost through our network. None of it requires a company to chase down outside consultants. It's a one-stop architecture designed to let founders run companies rather than manage vendor relationships.

Where Labs goes next, and what the new fund unlocks.

Labs today is a working engine with room to scale. The next fund accelerates three things: coverage of the new thesis areas Research is opening up, systematization of the playbooks so the machine scales beyond its current operators, and a deeper external function that helps portfolio technologies win on the ground.

Near Term
Bootcamp hardening. Codify the 6–8 week onboarding into a repeatable curriculum with case studies, metrics templates, and a standard diagnostic toolkit.
Near Term
Portfolio transition and coverage. Complete the transition of legacy portfolio companies onto the new Labs cadence and close coverage gaps in current thesis areas.
Mid Term
New thesis networks. Extend the subject-matter-expert and operator networks into the areas Research is opening — new physics, frontier biology, and other domains where the standard Bridgewater-alumni network is not enough.
Mid Term
Government relations function. Formalize the capability to help portfolio technologies navigate — and where needed, reshape — the policy environment they depend on.
Structural
Case study and training library. Turn the accumulating body of Labs interventions into systematized training that can be delivered to portfolio CEOs at scale, compounding the value of every lesson learned.
Structural
Venture studio expansion. Build out the in-house capability to create companies from scratch when a paradigm shift needs a piece that doesn't exist yet — then either scale it or sell it to a portfolio company that needs it.